Program Information
Development and Commissioning of a Complete System for In-Vivo Dosimetry and Range Verification in Proton Therapy
D Samuel1 , M Testa2 , R Schneider3 , Y Park4 , G Janssens5 , J Orban de Xivry6 , M Moteabbed7 , D Prieels8 , H Lu9 , E Bentefour10*, (1)Universite catholique de Louvain, Louvain-la-neuve, BW,(2) Massachusetts General Hospital, Boston, MA, (3)Massachusetts General Hospital, Boston, MA, (4) Massachusetts General Hospital, Boston, MA, (5) Ion Beam Applications, Louvain-la-neuve, Brabant Wallon, (6) Universite catholique de Louvain, Louvain-la-neuve, BW, (7)Massachusetts General Hospital, Boston, MA, (8) Ion Beam Applications, Louvain-la-neuve, Brabant Wallon, (9) Massachusetts General Hospital and Harvard Medical School, Boston, MA, (10) IAB, Warrenville, AA
Presentations
SU-E-T-435 Sunday 3:00PM - 6:00PM Room: Exhibit HallPurpose:
In-vivo dose and beam range verification in proton therapy could play significant roles in proton treatment validation and improvements. In-vivo beam range verification, in particular, could enable new treatment techniques one of which, for example, could be the use of anterior fields for prostate treatment instead of opposed lateral fields as in current practice. We have developed and commissioned an integrated system with hardware, software and workflow protocols, to provide a complete solution, simultaneously for both in-vivo dosimetry and range verification for proton therapy.
Methods:
The system uses a matrix of diodes, up to 12 in total, but separable into three groups for flexibility in application. A special amplifier was developed to capture extremely small signals from very low proton beam current. The software was developed within iMagX, a general platform for image processing in radiation therapy applications. The range determination exploits the inherent relationship between the internal range modulation clock of the proton therapy system and the radiological depth at the point of measurement. The commissioning of the system, for in-vivo dosimetry and for range verification was separately conducted using anthropomorphic phantom. EBT films and TLDs were used for dose comparisons and range scan of the beam distal fall-off was used as ground truth for range verification.
Results:
For in-vivo dose measurement, the results were in agreement with TLD and EBT films and were within 3% from treatment planning calculations. For range verification, a precision of 0.5mm is achieved in homogeneous phantoms, and a precision of 2mm for anthropomorphic pelvic phantom, except at points with significant range mixing.
Conclusion:
We completed the commissioning of our system for in-vivo dosimetry and range verification in proton therapy. The results suggest that the system is ready for clinical trials on patient.
Contact Email: